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Abstract
Background: Human herpes simplex virus (HSV) 1 and 2 causes oral, ocular, or genital infections, which remains a
significant health problem worldwide. HSV-1 and -2 infections in humans range from localized skin infections of
the oral, ocular, and genital regions to severe and often disseminated infections in immunocompromised hosts.
Epitope based vaccination is a promising mean to achieve protective immunity and to avoid infections with
Human herpes simplex virus type 2 (HSV-2).
Methods: The twelve selected epitopes, six B cell epitopes from different glycoprotein of HSV-2 (amino acid
residues 466-473 (EQDRKPRN) from envelope glycoprotein B, 216-223 (GRTDRPSA) from C, 6-18 (DPSLKMADPNRFR)
from D, 483-491 (DPPERPDSP) from E, 572-579 (EPPDDDDS) from G and 286-295 (CRRRYRRPRG) from I glycoprotein
of HSV-2), four CD4
+ T cell epitopes (amino acid residues 21-28 (NLPVLDQL) from D, 162-177
(KDVTVSQVWFGHRYSQ) from B, 205-224 (KAYQQGVTVDSIGMLPRFIP) from D and 245-259 (KPPYTSTLLPPELSD) from
D) and two CD8
+ T cell epitopes (amino acid residues 10-20 (KMADPNRFRGK) from D and 268-276 (ALLEDPAGT)
from D), are responsible for the elicitation of the neutralizing antibodies and cytotoxic T lymphocytes (CTLs) that
impart protective immunity to the host. In this study, all above epitopes were inserted into the extracellular
fragment (amino acid residues 1-290) of HSV-2 glycoprotein D to construct multi-epitope assembly peptides
(MEAPs) by replacing some non-epitope amino acid sequences. The epitope independency of the MEAPs was
predicted by three-dimensional software algorithms. The gene of the selected MEAP was expressed in E.coli BL21
(DE3), and its protective efficacy against HSV-2 infection was assessed in BALB/c mice.
Results: The MEAP, with each inserted epitopes independently displayed on the molecule surface, was selected as
candidate proteins. The results showed that the MEAP was highly immunogenic and could elicit high titer
neutralizing antibodies and cell-mediated immune responses.
Conclusions: The MEAP provided complete protection against infection with HSV-2 in mice, which indicates that it
might be a potential candidate vaccine against HSV-2.
Background
Human herpes simplex virus (HSV) 1 and 2 cause oral,
ocular, and genital infections, which construct a signifi-
cant health problem worldwide. HSV-1 and -2 infections
in humans range from localized skin infections of the
oral, ocular, and genital regions to severe and often
disseminated infections in immunocompromised hosts
[1]. After primary infection of mucosal epithelial cells,
the virus establishes lifelong latency in sensory neurons,
from which it periodically reactivates [2]. After reactiva-
tion, the virus migrates along the axons and infects cells
to the site of primary infection, causing painful blisters
on the surface of the lips in the case of HSV-1, or of
the genital mucosa for the closely related HSV-2 [3].
Four glycoproteins of the HSV-2, glycoprotein B (gB),
gD, gH and gL, have essential functions for HSV-2
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any medium, provided the original work is properly cited.entering into the host cells [4]. The cooperation of gB,
the heterodimer gH/gL, as well as gD and the gD recep-
tor are required in entering the plasma or endosomal
membrane of host cells [5,6]. The function of gD in
viral infectivity has been associated with the adsorption-
penetration process. It binds to the host cell at the posi-
tions of 52, 60 and 197-199 of gD in the amino acid
sequence. GB and gL, with the help from gK, are also
importantly associated with the adsorption-penetration
process [7,8].
During the last decade, HSV vaccine development has
primarily focused on various forms of recombinant gly-
coprotein. Recently, many approaches in vaccine devel-
opment have appeared, including one chemically
synthesized peptides covering only a small region of the
amino acid sequence of a protein [9]. It was reported
that B cell epitopes from the amino acid sequence of
gD2 could induce mice to produce antibodies against a
potent and type-common antiviral activity, and some B
cell epitopes of HSV-2 glycoprotein have been identified
[10].
Neutralization antibodies to HSV-2 (B cellular immu-
nity) play a prominent role in prophylactic protection
from infection in animal models, while CD4
+ T cell-
based cellular immunity to HSV-2 may play an impor-
tant role in controlling recurrent human disease. Despite
previous emphasis on antibody (Ab) and CD8
+ Tc e l l
responses, there is growing evidence to support a pivotal
role for the CD4
+ T cells in antiherpesvirus immunity.
CD4
+ T cells are required for the protection of mice
from HSV-2 challenge [11]. Severe herpetic infections
are often seen in immunocompromised individuals with
impaired CD4
+ T cell immunity, such as those with
AIDS and transplant patients, which indicate that CD4
+
T cells are very important for protection against virus
infection. It is believed that CD4
+ T cell responses are
important for protection against HSV-2 infection. These
findings, along with the important role of CD4
+ T, CD8
+ T and B cells, suggested that a successful immunopro-
phylactic and immunotherapeutic strategy against HSV-
2 should include immunodominant CD4
+ Ta n dC D 8
+
T cell epitopes.
It is necessary to develop an effective vaccine against
HSV-2 that can stimulate the body to produce both
cell-mediated and humoral immunity. Therefore, it is
expected that a novel HSV-2 vaccine should be devel-
oped through the selection of immunodominant epi-
topes of CD4
+ T, CD8
+ T and B cell. In this study,
twelve selected epitopes, six B cell epitopes, four CD4
+
Ta n dt w oC D 8
+ T cell epitopes, were all inserted into
the extracellular fragment (1-290) of HSV-2 glycoprotein
D to construct multi-epitope assembly peptides
(MEAPs) by replacing some non-epitope amino acid
sequences. The results showed that the MEAP expressed
by bioengineering had strong and specific antigenicity
and was able to strongly induce Th1 and Th2 cytokine
(IL-2, IL-4 and IFN-g) secretion, providing a basis for
the development of novel vaccines against HSV-2.
Materials and methods
Virus and cell lines
Vero cells were grown in medium 199 supplemented
with 10% fetal calf serums 100 U/ml penicillin, 0. 1 g/L
streptomycin (all from GIBCO, USA) for use. Target cells
(NIH 3T3 cells) was kindly provided by Prof. Liu (Anhui
Medical University, China) and used as target cells for
CTL assay. Monolayers were infected with HSV-2, Sav
strain. Inactivated virus was prepared by infection of cells
at a multiplicity of 0.1. After 4 days, extracellular virus
was isolated and heat-inactivated for 30 min at 56°C, and
stored at -80°C. Infectious virus (for animal protection
experiments) was prepared by infecting cells at a multi-
plicity of 10. Medium was removed at 18 h after infec-
tion, and the cells were scraped into a small volume.
Cells were sonicated and debris was removed by low
speed centrifugation. The supernatant was stored at -80°
C. The number of infectious virus particles was deter-
mined by a plaque assay. Briefly, virus dilutions were pla-
ted on monolayers of Vero cells in six well trays. Overlay
medium containing 0.5% methyl cellulose was added.
After 3 days, the monolayers were fixed and subsequently
stained with Giemsa. Plaques were counted and the titers
expresses as pfu per ml.
Design of MEAPs
The twelve selected epitopes, six B cell epitopes (gB2466-
473, gC2216-223, gD26-18, gE2483-491, gG2572-579 and gI2286-
295), four CD4
+ T cell epitopes (gD221-28,g D 2 205-224,
gD2245-259 and gB2162-177) and two CD8
+ T cell epitopes
(gD210-20 and gD2268-276), which all identified by further
experiments (data no shown), were inserted into the
extracellular fragment (1-290) of HSV-2 glycoprotein D
to construct multi-epitope assembly peptides (MEAPs)
by replacing some non-epitope amino acid sequences
[9,12]. In order to find a homology model for suitable
protein structure template, homologous protein
sequences were searched using the protein blast method
in the PDB database of the United States National Cen-
ter for Biotechnology Information (NCBI). The results
showed that the highest score from 1JMA was about
84% (30% protein homology is considered as a condition
of homology modeling). So, 1JMA was used as a tem-
plate for homology modeling of the multi-epitope
assembly peptides (MEAPs). The structures the MEAPs
were analyzed by Accelrys Discovery Studio and
Moe2008 software, only the MEAPs with inserted epi-
topes independently displayed on the surface were
selected as candidate proteins.
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The gene of a selected MEAP was chemically synthe-
s i z e d( b yJ i n s i t eC o m p a n y ,C h i n a ) ,a n dc l o n e di n t ot h e
sites between BamHIand XhoIof plasmid pET28a
(+)-sumo to construct a recombinant expression vector
of pET28a (+)-sumo-MEAP, and thereafter transformed
into E. coli BL21 for expressing a sumo-MEAP fusion
protein. The engineered E.coli BL21 was cultured and
induced by 1mM IPTG (Promega) at 25°C for 4 h. The
induced engineered E. coli BL21 was collected by centri-
fugation, and lysised by ultrasound, the lysis supernatant
was harvested by centrifugation, and concentrated by
ultrafiltration.
Ni Sepharose 6 Fast Flow (GE Healthcare, Sweden)
was suspended by gently rocking the bottle, an adequate
amount of slurry was draw into a container through a
pipe. The gel was washed with cold PBS (4°C), and
thereafter, mixed with the lysis supernatant containing
the expressed sumo-MEAP fusion protein. After oscilla-
tion for 30 min and centrifugation at 500 rpm for 5 min
at room temperature, the supernatant was discarded and
the precipitated gel was resuspended with washing buf-
fer and loaded to a column, the gel was washed comple-
tely with washing buffer. The proteins were sequentially
eluted from the column by gradient imidazole solutions
(25, 50, 100, 150, 200 and 250 mM) in Tris-HCl (250
mM pH 8.5). The eluted parts were collected for detec-
tion of the purified sumo-MEAP fusion protein by SDS-
PAGE. The elution fusion protein was dialyzed against
Tris-HCl (50 mM pH 8.0), then 50 μgo fs u m o - M E A P
was digested with 1 μl of sumo proteinase (Biotsith,
Suzhou, China) with 2 U/μl at 22°C for 16 h. The diges-
tion mixture was loaded on a Ni Sepharose 6 Fast Flow
(GE Healthcare, Sweden) column in order to eliminate
the sumo and sumo-MEAP that was not digested by
sumo proteinase, and then was detected by SDS-PAGE
electrophoresis.
Immunization of mice
Thirty KunMing Mice (4-6 weeks old, male), were ran-
domly divided into three groups. Each group was subcu-
taneously injected with MEAP, inactivated vaccine and
PBS respectively. The immunization program as follows,
the first injection with 4 μg of the purified MEAP (98%)
emulsified in complete Freund’s adjuvant, after 2 weeks,
2 μg of the purified MEAP emulsified in incomplete
Freund’s adjuvant was injected subcutaneously. The
third injection was as that of the second. PBS, or inacti-
vated vaccine was injected using the same procedure as
MEAP immunization. Serum samples were collected on
weeks 2, 3, 4 and 5 weeks after the first injection.
Serum samples were separated and stored at -20°C for
further assays. Two weeks after the final immunization,
the mice were sacrificed, and their spleens removed
aseptically for in vitro splenocyte culture. The antigeni-
city and immunity analysis of the MEAP were per-
formed by EIA. Specific serum IgG antibodies to MEAP
were determined with an endpoint EIA using purified
MEAP as antigen with 100 μl( 2 . 5μg/ml) in each well
as described previously [13]. The titers were expressed
as the reciprocal of highest dilution of sera producing
ratio values of 2.1. The selected synthesized B cell epi-
topes were coated as antigens in 96-well plate with 100
μl( 2 . 5μg/ml) in each well. The antigenicities of B cell
epitopes were detected by EIA with antibody to the
MEAP. On the other hand, in order to detect the
MEAP antigenicity, the MEAP was coated as an antigen
in 96-well plate with 100 μl( 2 . 5μg/ml) in each well.
The MEAP antigenicities against the antibodies to the
B, C, D, E, G and I glycoproteins (ABcam) were
detected by EIA. All animal work was approved by the
Anhui Administrative Committee for Laboratory
Animals.
Virus neutralization tests in vitro
Virus neutralization assay was performed using the pro-
cedures described by Cha et al.[ 1 4 ]a n dK a n get al.
[15]. Neutralization antibodies elicited in immunized
mice blood from each group was heated at 56°C for 30
min to inactivate the complement. A 100 μ1o ft h e
heat-inactivated serum was added into a 96-well-flat-
bottom microtiter plate for serial dilution (Falcon, Lin-
c o l nP a r k ,N J ,U S A ) .A1 0 0μ1o f2 0 0×T C I D 50 of the
live Sav strain of HSV-2 was added to the plate, sealed
and incubated for 18 h at 40°C. Then 100 μ1o f5×1 0
3
viable Vero cells were added to each well and incubated
at 37°C for 5 days. The serum dilution factor that neu-
tralized 50% of the virus was determined as the titer.
The TCID50 was 0.69 pfu as determined by the proce-
dure described by Reed and Muench [16]. Each serum
sample was assayed in triplicate.
Cytokine profiling
The vaccinated mice, from the above, were sacrificed to
recover splenocytes 2 weeks after final immunization.
The splenocytes were incubated in 96-well flat-bottomed
microtiter plates (100 μ1/well of 5 × 10
6 cell/ml in
RPMI 1640 medium with 10% FCS). The MEAP protein
was added at a final concentration of 10 μg/ml. After
incubation for 72 h, the splenocyte culture supernatants
were collected for cytokine detection. The presence of
the cytokines IL-2, IL-4 and IFN-g in supernatant from
the splenocytes cultured from vaccinated mice was
examined using commercial murine cytokine EIA kits
(Biosource USA), following the manufacturer’s
instructions.
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The CTL assay was performed as described earlier [17].
Briefly, mixed splenocytes from 10 mice in each group
were stimulated with the MEAP protein (10 μg/ml) in 1
ml of RPMI 1640 medium with 10% FCS in 24-well
microplates at 37°C for 6 days. Target cells (NIH 3T3
cells) were prepared by infection with the HSV-2 Sav
for 20 h before the assay. The target cells were distribu-
ted into triplicate wells of a 96-well plate (5 × 10
3 cells
per well) and the ratio of effector to target cells was
adjusted to 50: 1. The effector and target cells were
mixed and incubated at 37°C for 6 h before the superna-
tant was collected. Lactate dehydrogenase (LDH) activity
released into the culture medium was measured with a
cytotoxicity assay kit (Promega, USA), according to the
manufacturer
’ s instructions.
Animal protection experiments
The mice (8 weeks old, BALB/c, female), 10 each group
for three groups, were immunized with 4 μg of the MEAP,
inactivated vaccine and PBS as control, were challenged
with the Sav strain. At 2 weeks after the final vaccination
was injected, the anesthetized mice were challenged with
the Sav strain. In order to synchronize the estrus cycle at
the progesterone-dominated stage, the immunized and
sham-immunized mice were subcutaneously injected with
2 mg of progesterone (Jinsite, China) in 50 μ1o fH 2 Op e r
mouse. At 5 days after the administration of progesterone,
the mice of all groups were infected with the Sav strain
into vagina and external genital skin. One hour prior to
infection, the vaginal closure membrane was ruptured
with a saline-moistened cotton swab. The swab was
inserted into vagina, twisted back and for five times, then
removed and wiped over the external genitalia. To ensure
infection, a virus application was repeated 1 h later. The
infected mice were examined daily for vaginal inflamma-
tion, neurological illness, and death, and then were scored
in steps 1-5 depending on the severity of disease as
described by the reported papers [17,18]. Vaginal washings
were collected on days 1, 2, 3, and 4 post inoculation after
the intravaginal challenge with pipetting 100 μlo fP B S
into the vaginal cavity. The samples were stored at -20°C
until used. They were added to 1 ml of the media, and
were subsequently infected and titered on Vero cell mono-
layers by using a plaque assay. Viral neutralization titers in
the vaginal secretion samples of the day 4 post inoculation
were measured using a micro-neutralization assay
described above. The immunized mice were intravaginal
challenged with lethal dosages (5 × 10
6 pfu: 500LD50)o f
the Sav strain. The vaginal external diseases were exam-
ined daily for signs of inflammation and measured mean
daily lesion scores on Day 1-14 following infection. The
severity of the primary disease was assessed by the lesion
scoring system [19,20]. In addition, survival of the
vaccinated mice challenged with the Sav strain were daily
measured and summarized.
Statistical analysis
Data were expressed as means ± standard error (SE).
Student’s t-test or analysis of variance (ANOVA) was
used for determine the differences among the groups,
using the SPSS software package (version 16.0, SPSS
Inc., Chicago, IL, USA). A value of P < 0.05 was consid-
ered statistically significant.
Results
Prediction of epitopes independency of MEAP
The twelve epitopes, including six B, four CD4
+ Ta n d
two CD8
+ T cell epitopes, were used for construction of
the MEAPs. The six B (gB2466-473,g C 2 216-223,g D 2 6-18,
gE2483-491,g G 2 572-579and gI2286-295), four CD4
+ T
(gD221-28,g D 2 205-224,g D 2 245-259and gB2162-177) and two
CD8
+ T cell epitopes (gD210-20and gD2268-276), were
inserted into the extracellular fragment (1-290) of HSV-
2 glycoprotein D to construct multi-epitope assembly
peptides (MEAPs) by replacing some non-epitope amino
acid sequences. Three-dimensional structures of the
designed 14 MEAPs were predicted for screening the
MEAP in which all the B cell epitopes independently
displayed on the surface of the MEAP. The MEAP
selected for preparation by genetic engineering was
shown in Figure 1 and Figure 2.
Expression and purification of sumo-MEAP
The gene of the selected MEAP was synthesized chemi-
cally and cloned into plasmid pET28a (+)-sumo, the
recombinant plasmid pET28a (+)-sumo-MEAP was con-
firmed by DNA sequencing and was transferred into E.
coli BL21, the expression of recombinant protein was
induced by IPTG and screened by SDS-PAGE analysis.
Due to a sumo tag located at the N-terminal of the
MEAP, the molecular weight of expressed sumo-MEAP
fusion protein was approximately 40 kD. The expressed
sumo-MEAP was about 20% of the total bacterial proteins
and largely existed in soluble form. The results indicated
that the recombinant protein sumo-MEAP was success-
fully expressed. The sumo-MEAP was purified by Ni
Sepharose 6 Fast Flow and detected by SDS-PAGE. The
sumo-MEAP was predominantly contained in the elution
of 100 mM imidazole. In order to remove the sumo,
sumo-MEAP was digested by sumo proteinase at 22°C for
2 h, then purified by Ni Sepharose 6 Fast Flow, the col-
lected eluent was detected by SDS-PAGE (Figure 3).
Anti-MEAP IgG antibody titers in the sera of immunized
mice
All the mice immunized with the MEAP produced the
antibodies to the MEAP at the titer from 1: 400 to 1:
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selected to confirm the immunity of the B cell epitopes
by EIA using B cell epitopes as antigens. Also, the
MEAP was used as the antigen to detect the corre-
sponding antibodies against gB2, gC2, gE2, gG2, gI2 and
gD2 by EIA. All B cell epitopes, except gG2572-579, could
react with the antiserum against the MEAP, and the
MEAP could react with all the antibodies against the six
glycoproteins, but only weakly with the antibodies
against gG2 (Table 1). The results indicated that the
MEAP had good antigenicity and immunity, and implied
that the five B cell epitopes, gB2466-473, gC2216-223, gD26-
18,g E 2 483-491 and gI2286-295, were displayed on the sur-
face of the MEAP molecule, which was consistent with
the prediction. Mice were immunized with the MEAP,
inactivated vaccine and PBS by the subcutaneously
injection. Serum samples (10 mice per group) were col-
lected at various time points, and endpoint antibody
titers against HSV-2 were determined by EIA. The
MEAP, inactivated Sav strain and PBS were used to coat
in EIA. The result was shown in Figure 4.
Virus neutralization activity of antisera
Serum samples collected on day 14 were evaluated for
their ability to neutralize HSV-2 by serum neutralizing
assay. Virus-neutralization activity of the antisera against
MEAP, inactivated vaccine and PBS were tested by 50%
plaque reduction assay. The neutralizing titer of the
antiserum from the mice, which were immunized with
the MEAP, had a neutralizing antibody titer of 1/1208.
The neutralization titers of antiserum form mice immu-
nized with inactivated vaccine is 1/564. The mice anti-
sera from the PBS-vaccinated mice showed little or no
neutralizing activity.
Th1-type and Th2-type cytokine responses were analyzed
in immunized mice
The splenocyte culture supernatant was harvested at 72
h after stimulation to determine the production of dif-
ferent cytokines (IL-2, IL-4 and IFN-g). Splenocytes
from the mice immunized with MEAP induced the
highest level of IL-4 (311.23 ± 6.57 pg/ml) among the
three groups. The levels of IL-2 and IFN-g were 149.97
Figure 1 Three-dimensional of epitopes of MEAP. 1 J M Aw a su s e da sat e m p l a t ef o rh o m o l o g ym odeling of the multi-epitope assembly
peptides (MEAPs). The three-dimensional structures of the MEAP were analyzed by software algorithm Moe2008, while the three-dimensional of
epitopes were depicted as follows: Three-dimensional B cell epitopes can be seen in A and B, and A is the obverse side opposite to B. Three-
dimensional CD4
+ T and CD8
+ T cell epitopes can be seen in C and D, and C is the obverse side opposite to D.
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strated that splenocyte from the mice immunized with
MEAP induced predominantly Th-2 (IL-4)-type cellular
immune response, because the levels of Th-2 (IL-4)-type
cytokines were higher than those of Th1 (IL-2 and IFN-
g)-type cytokines. Splenocyte from the mice immunized
with the inactivated vaccine made only small amounts
of IL-4 (119.21 ± 6.98 pg/ml); nevertheless, they induced
high levels of IFN-g (219.33 ± 6.99 pg/ml) and IL-2
(181.70 ± 17.43 pg/ml). Splenocyte from the mice that
received PBS did not produce any significant cytokine
titers (Figure 5).
Cytokine T lymphocytes (CTL) among splenocyte
stimulated with MEAP in vitro
The highest level of CTL activity was observed in the
group of splenocyte treatment with MEAP in cytotoxi-
city assay, followed by the groups inoculated with the
inactivated vaccine and PBS. The mean CTL activity of
MEAP treatment group, inactivated vaccine treatment
Figure 2 Design and construction a multi-epitope assembly peptide (MEAP). The MEAP were constructed from six B cell epitopes (gB2466-
473, gC2216-223, gD26-18, gE2483-491, gG2572-579 and gI2286-295), four CD4
+ T (gD221-28, gD2205-224, gD2245-259 and gB2162-177) and two CD8
+ T cell
epitopes (gD210-20 and gD2268-276) with some non-epitope amino acid sequences of the extracellular fragment (1-290) of HSV-2 glycoprotein D
as spacers between epitopes.
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and 12. 21 ± 1.51%, respectively. The CTL responses
from the group immunized with MEAP were signifi-
cantly higher than those from the groups given the inac-
tivated vaccine or PBS (P < 0.01) (Figure 6).
Animal protection experiments
The immunized mice were intravaginal challenged with
lethal dosages (5 × 10
6 pfu: 500LD50)o ft h eS a vs t r a i n .
The vaginal external diseases were examined daily for
signs of inflammation and measured mean daily lesion
scores on day 1-14 following infection. The severity of
the primary disease was assessed by the lesion scoring
system [19,20]. The negative vaccination developed
severe diseases and had no effect after 3 days, but the
MEAP immunized groups were completely protected
from death. The inactivated vaccine immunized mice
also showed a high protection level of the lesion score 1
stage from day 4. These results indicated that the
Figure 3 MEAP purification by Ni Sepharose 6 Fast Flow.L a n e
1: Supernatant. Lane 2: Flow-through. Lane 3: Elution. Lane 4: Sumo-
MEAP digested by sumo protease. Lane 5: Purified MEAP. Lane M:
Protein marker. Note: Red, blue and black arrow indicate the
purified the sumo-MEAP, the MEAP and the sumo tag, respectively.
Table 1 Antigenicities of the MEAP with antibodies to B,
C, D, E, G and I glycoprotein of HSV-2 and antigenicities
of some B cell epitopes with antibodies to the MEAP
No. Antibodies EIA OD (450 nm) Value
gD26-18 Ab to MEAP 1.125 ± 0.041
gB2466-473 Ab to MEAP 0.977 ± 0.039
gC2216-223 Ab to MEAP 0.899 ± 0.031
gE2483-491 Ab to MEAP 1.102 ± 0.040
gG2572-579 Ab to MEAP 0.182 ± 0.011
gI2286-295 Ab to MEAP 0.792 ± 0.029
MEAP Ab to gD2 1.099 ± 0.037
MEAP Ab to gB2 0.986 ± 0.031
MEAP Ab to gC2 0.893 ± 0.029
MEAP Ab to gE2 1.013 ± 0.041
MEAP Ab to gG2 0.201 ± 0.011
MEAP Ab to gI2 0.876 ± 0.031
Control 1 Ab to MEAP 0.116 ± 0.011
Control 2 Ab to gD2 0.121 ± 0.010
The selected synthesized B cell epitopes were coated as antigens. The
antibodies to the MEAP reacted with the epitopes. The antigenicities were
detected by EIA. The MEAP was coated as an antigen. The antibodies to the B,
C, D, E, G and I glycoproteins (ABcam) reacted with the MEAP, and the results
can be seen in the Table. No. represents the number of the peptides and the
MEAP. Control 1 is a peptide other from the HSV-2 glycoproteins. Control 2 is
a antibody other than antibodies to the B, C, D, E, G and I glycoproteins of
HSV-2. The O.D. mean values (at 450 nm) are shown in the Table.
Figure 4 Antibody response in mice. Group of BALB/c mice were
immunized with the MEAP, inactivated Sav vaccine and PBS. Serum
samples (10 mice per group) were collected at various time points,
and endpoint antibody titers against HSV-2 were determined by EIA.
All the measurements were made in triplicate, with the mean ±
standard error (SE) shown. P < 0.05 compared with groups
immunized with PBS or inactivated vaccine.
Figure 5 Cytokine detection in splenocyte culture supernatants
from vaccinated mice. Splenocyte samples (10 mice per group)
isolated from the spleens of vaccinated mice on day 14 after the
last immunization against the MEAP. After 72 h, the supernatants
were collected to examine the levels of the Th1- type cytokine IL-2,
IFN-g and the Th2-type cytokine IL-4 using commercially available
murine cytokine EIA kits. All the measurements were made in
triplicate, with the mean ± standard error (SE) shown. P < 0.05
compared with groups immunized with PBS or inactivated vaccine.
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vaccine had protective effect on HSV-2 infection.
The MEAP and inactivated vaccine immunized groups
completely survived during experiments, while the PBS
vaccination mice developed severe diseases with all the
mice dead after 5 days post the infection (Figure 7).
Virus multiplication was also observed in the genital
tracts of all immunized mice on 4th days post infection.
The virus was isolated in vaginal tracts with cotton swabs
from the immunized mice. Virus titers in the immunized
mice on days 1, 2, 3 and 4 post intravaginal infection
were significantly reduced than that of the negative con-
trol (PBS). Also, each vaccinated group demonstrated
that the viral titers decreased with time. On day 1, viral
titer of the MEAP immunized mice decreased 4.76 fold
than that of the PBS negative control group. Viral titers
of the inactivated vaccinated mice were nearly similar to
the MEAP immunized mice. On day 4, the virus titer
decreased about 4.07 times in the inactivated vaccinated
mice and 4.18 times in the MEAP immunized mice than
that of the PBS control. These results indicated that virus
in MEAP immunized mice and inactivated vaccinated
mice were cleared more rapidly from the genital tracts of
mice than in PBS treatment mice (P <0 . 0 5 ) ,a n dt h e
MEAP has better protective effect against the HSV-2
infection with lethal dosage.
Discussion
The potential advantages of an epitope based vaccine
are as follows. First, epitope based vaccines represent a
powerful approach to induce a specific immune
response against the selected epitope (s), avoiding the
side effects of other unfavorable epitopes in the com-
plete antigen [21]. Second, epitope based vaccine has
other considerable advantages, including increased
safety, the opportunity to engineer the epitopes ration-
ally for increased potency and breadth, and the ability to
focus the immune response on conserved epitopes [22].
Moreover, the epitope based vaccine approach has been
shown to be successful in various infectious diseases,
such as Neisseria meningitides infection, and tuberculo-
sis [23]. In this study, an epitope based vaccine was pro-
posed as a possible candidate vaccine with a remarkable
ability to induce protection against HSV-2 infection.
B cell antigenic epitopes from HSV-2 glycoproteins
were screened using three software algorithms: Biosun,
DNAstar, and Antheprot algorithms. The common
results from software were used as candidate epitopes of
B cell epitopes. In this study, six B cell epitopes (gB2466-
473, gC2216-223, gD26-18, gE2483-491, gG2572-579 and gI2286-
295) were predicted and identified as epitopes (data no
shown), which have not been reported. CD4
+ T cell epi-
topes were predicted successively by the APC software
algorithm, the lysosome hydrolysis cleavage site software
algorithm and the TAP software algorithm. The results
of the APC software algorithm provided candidate pep-
tides for the lysosome hydrolysis cleavage site software
algorithm. Similarly, the results of the lysosome hydroly-
sis cleavage site software algorithm provided candidate
peptides for the TAP bind software. Some CD4
+ Tc e l l
immunodominant epitopes, which had higher affinity to
TAP than ICP47, were screened as candidate CD4
+ T
cell epitopes [24]. Four of them (gD221-28,g D 2 205-224,
gD2245-259 and gB2162-177) were identified as epitopes
(data no shown), which have not been reported. Here,
epitope-prediction program SYFPEITHI, NetMHC and
M H C P r e dw e r eu s e dt oa n a l y z et h es e q u e n c eo fg D 2
according to their different algorithms. Two CD8
+ T
cell immunodominant epitopes, gD210-20 and gD2268-276,
were predicted and identified as epitopes (data no
shown) [25], which have not been reported.
T h eg D 2 ,g B 2 ,g C 2 ,g E 2 ,g G 2a n dg I 2o fH S V - 2a r e
largely exposed structural glycoprotein, which have B-
Figure 6 CTL activity of splenocytes from vaccinated mice 2
weeks after the last immunization. Splenocyte samples (10 mice
per group) isolated from the vaccinated mice were stimulated with
the MEAP. After 6 days the CTL activities were detected using a
cytotoxicity assay kit by measurement of the LDH released. All the
measurements were made in triplicate, with the mean ± standard
error (SE) shown. P < 0.05 compared with groups immunized with
PBS or inactivated vaccine.
Figure 7 Survival of vaccinated mice following lethal
intravaginal challenge with HSV-2 Sav strain. Mice were
vaccinated three times and then intravaginally challenged with a 5
×1 0
6 pfu of lethal doses of the strain as described in the section
Materials and Methods. Symbols: MEAP- black triangle, inactivated
vaccine - white circle, PBS - black circle.
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antigen [26]. Ideally, epitope based vaccines should con-
tain both B cell epitopes, which are essential for the
protective antibody response, and T cell epitope (CTL
epitopes, Th epitopes) that will serve to induce CTL and
Th immune responses. Therefore, in the present study,
we selected six B cell epitopes (gB2466-473,g C 2 216-223,
gD26-18, gE2483-491, gG2572-579 and gI2286-295), four CD4
+
T cell epitopes (gD221-28,g D 2 205-224,g D 2 245-259 and
gB2162-177)a n dt w oC D 8
+ T cell epitopes (gD210-20 and
gD2268-276) from HSV-2 glycoproteins to construct an
epitope based vaccine (MEAP). These confirmed epi-
topes were all inserted into the extracellular fragment
(1-290) of HSV-2 glycoprotein D to construct multi-epi-
tope assembly peptides (MEAPs) by replacing some
non-epitope amino acid sequences. Three-dimensional
structures of the 14 MEAPs were predicted by the soft-
ware algorithms of Accelrys Discovery Studio and
Moe2008 in order to screen a MEAP. All epitopes, espe-
cially the B cell epitopes, independently displayed on the
surface of the MEAP [12,27,28].
HSV-2 specific IgG response was detected in the sera
of mice immunized with MEAP after three boosts, as
well as in the mice immunized with inactivated vaccine.
This suggests that the MEAP protein and inactivated
vaccine were both capable of inducing a significant
humoral response in mice. Studies have demonstrated
that neutralizing antibodies are important for protection
against HSV-2 infection and titers ≥ 1:10 are considered
to be indicative of protective immunity [29]. The mean
neutralization titer in the mice immunized with MEAP
was 1208 after the third boost, and these titers were
higher than those induced by the inactivated vaccine (P
< 0.05). Importantly, these antibody titers were sufficient
to protect mice against HSV-2 infection, which indicates
the potential of MEAP as a vaccine against HSV-2.
In addition, Cell-mediated immunity plays an impor-
tant role in efficient protection. The results of cytokine
assay and CTL activity indicated that CTL activity and
the level of Th2-type cytokines (IL-4) produced in the
culture supernatant from mice vaccinated with MEAP
was significantly higher than in the groups given inacti-
vated vaccine and PBS. This demonstrated that the
multi-epitope vaccine, MEAP, constructed in this study
stimulated intensive cellular immunoreaction. Specific
CTL are critical in the recovery from infection and the
clearance of HSV-2, and the Th2 immune response
against HSV-2 is also protective [30], the remarkably
increased CTL activity and IL-4 production in the
MEAP group may indicated that the MEAP has a higher
degree of protection effect.
Challenge experiments showed that the mice that
received the MEAP or the inactivated vaccine were
completely protected against HSV-2 infection, even
though the mean neutralizing antibody titer before chal-
lenge of the group vaccinated with the MEAP was lower
than that of the group given the inactivated vaccine.
This high level of protection, also, is usually related to
the MEAP specific neutralizing antibodies [31]. How-
ever, we observed high levels of CTL activity in the sple-
nocytes of the mice immunized with the MEAP. This
may be contributed to the high levels of protection in
the mice immunized with the MEAP, because CTL
activity by the T cells was found also to be an essential
determinant of protective immunity against HSV-2 [32].
Conclusions
We have constructed a recombinant multi-epitope assem-
bly peptide (MEAP) from HSV-2 using epitope based vac-
cine strategies. These results indicated that MEAP was
capable of inducing remarkable humoral and cellular
immune responses and provided complete protection
against lethal challenge in mice. These demonstrate that
the MEAP may be a promising subunit vaccine candidate
for the prevention of HSV-2 infection. The present study
also provided useful information for the further develop-
ment of multi-epitope vaccine for human.
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